Benzinga | Aug 4, 2020 07:09AM EDT

REGENXBIO Announces Additional Positive Interim Phase 1/2a Trial Update And Program Updates For RGX-314 For Treatment Of Wet AMD

* Company on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020

* RGX-314 was generally well-tolerated in 42 patients at all dose levels in Phase I/IIa trial

* Positive interim update from Cohorts 4 and 5 at one year informs pivotal program Durable treatment effect observed with stable to improved visual acuity and retinal thickness Demonstrated meaningful reductions in anti-VEGF treatment burden over one year 61% and 85% reduction of anti-VEGF injections in Cohorts 4 and 5, respectively 73% of patients (8/11) in Cohort 5 remain anti-VEGF injection-free Intraocular RGX-314 protein expression levels are dose-dependent at one year

* Phase II trial for RGX-314 for the treatment of wet AMD using suprachoroidal delivery (AAVIATE) is active Enrollment expected to begin in Q3 2020; interim data update from first cohort expected by end of 2020

* Company to host conference call and webcast on Tuesday, August 4 at 8:30a.m. ET, featuring wet AMD Key Opinion Leaders, Robert Avery, M.D., Dante Pieramici, M.D., and Peter Kaiser, M.D.